Literature DB >> 7518451

Identification of interleukin-2 receptor-associated tyrosine kinase p116 as novel leukocyte-specific Janus kinase.

R A Kirken1, H Rui, M G Malabarba, W L Farrar.   

Abstract

Janus tyrosine kinase (JAK) has recently been linked to signal transduction by cytokine receptors of the hematopoietin family. We have recently described a 116-kDa tyrosine kinase (p116) present in interleukin-2 (IL-2) receptor complexes in human YT cells that showed functional characteristics of a JAK kinase. These included receptor association, rapid and transient tyrosine phosphorylation kinetics in response to ligand, and in vitro autophosphorylating tyrosine kinase activity (Kirken, R. A., Rui, H., Evans, G. A., and Farrar, W. L. (1993) J. Biol. Chem. 268, 22765-22770). Here we extend these observations by demonstrating structural homologies between IL-2-modulated p116 and prolactin-modulated JAK2 in the rat T cell line Nb2. These include similar net charge as determined by nonequilibrium pH gradient electrofocusing and related primary structure based upon phosphopeptide mapping of V8 protease-digested hyperphosphorylated proteins. This putative JAK kinase underwent marked tyrosine phosphorylation in response to IL-2, IL-4, and IL-7, lymphoid growth factors that use the common IL-2 receptor gamma-chain, but not in response to prolactin. Furthermore, polyclonal antisera to JAK1, JAK2, or tyrosine kinase 2 did not recognize either rat or human p116. However, we identified the IL-2-modulated p116 as the recently cloned novel leukocyte Janus kinase, L-JAK, using an antiserum to a peptide corresponding to the COOH terminus of human L-JAK.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518451

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Interleukin-2 Receptor β Thr-450 Phosphorylation Is a Positive Regulator for Receptor Complex Stability and Activation of Signaling Molecules.

Authors:  Blanca E Ruiz-Medina; Jeremy A Ross; Robert A Kirken
Journal:  J Biol Chem       Date:  2015-07-07       Impact factor: 5.157

2.  Structural domains of interleukin-2 receptor beta critical for signal transduction: kinase association and nuclear complex-formation.

Authors:  O M Howard; R A Kirken; G G Garcia; R H Hackett; W L Farrar
Journal:  Biochem J       Date:  1995-02-15       Impact factor: 3.857

3.  The combination of insulin-like growth factor 1 and erythropoietin protects against ischemic spinal cord injury in rabbits.

Authors:  Kohji Utada; Kazuyoshi Ishida; Suguru Tohyama; Yutaka Urushima; Yoichi Mizukami; Atsuo Yamashita; Masato Uchida; Mishiya Matsumoto
Journal:  J Anesth       Date:  2015-05-24       Impact factor: 2.078

4.  Molecular mechanisms regulating the hyaluronan binding activity of the adhesion protein CD44.

Authors:  R K Chiu; A Droll; D L Cooper; S T Dougherty; J F Dirks; G J Dougherty
Journal:  J Neurooncol       Date:  1995-12       Impact factor: 4.130

5.  Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha.

Authors:  M G Malabarba; H Rui; H H Deutsch; J Chung; F S Kalthoff; W L Farrar; R A Kirken
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

Review 6.  X-linked severe combined immunodeficiency disease and the gamma c receptor component: prospects for molecular diagnosis.

Authors:  N L Farner; S D Voss; P M Sondel
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

7.  Elf-1 and Stat5 bind to a critical element in a new enhancer of the human interleukin-2 receptor alpha gene.

Authors:  P Lécine; M Algarté; P Rameil; C Beadling; P Bucher; M Nabholz; J Imbert
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

8.  NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3.

Authors:  Byung-Hak Kim; Jun-Goo Jee; Chang-Hong Yin; Claudio Sandoval; Somasundaram Jayabose; Daisuke Kitamura; Erika A Bach; Gyeong-Hun Baeg
Journal:  Mol Cancer       Date:  2010-02-11       Impact factor: 27.401

9.  MS-1020 is a novel small molecule that selectively inhibits JAK3 activity.

Authors:  Byung-Hak Kim; Sei-Ryang Oh; Chang-Hong Yin; Sangku Lee; Eun-Ah Kim; Min-Seok Kim; Claudio Sandoval; Somasundaram Jayabose; Erika A Bach; Hyeong-Kyu Lee; Gyeong-Hun Baeg
Journal:  Br J Haematol       Date:  2009-09-29       Impact factor: 6.998

10.  Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.

Authors:  Byung-Hak Kim; Eun Hee Yi; Jun-Goo Jee; Ae Jin Jeong; Claudio Sandoval; In-Chul Park; Gyeong Hun Baeg; Sang-Kyu Ye
Journal:  J Cell Mol Med       Date:  2020-06-17       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.